Vanda Pharmaceuticals general counsel to resign
Vanda Pharmaceuticals Inc. reported that Timothy Williams has resigned as Senior Vice President, General Counsel and Secretary.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Vanda Pharmaceuticals Inc. reported that Timothy Williams has resigned as Senior Vice President, General Counsel and Secretary. He notified the company on March 29, 2026, and his resignation will be effective April 10, 2026, as he plans to pursue other endeavors.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Notification date: March 29, 2026
Effective resignation date: April 10, 2026
Filing date: April 2, 2026
3 metrics
Notification date
March 29, 2026
Date Timothy Williams notified Vanda of his resignation
Effective resignation date
April 10, 2026
Date Timothy Williams’ resignation becomes effective
Filing date
April 2, 2026
Date Vanda Pharmaceuticals submitted the Form 8-K
Key Terms
Form 8-K, Senior Vice President, General Counsel and Secretary, Securities Exchange Act of 1934, emerging growth company
4 terms
Form 8-K regulatory
"FORM 8-K Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934"
A Form 8-K is a report that companies file with the government to share important news quickly, such as changes in leadership, major business deals, or financial updates. It matters because it helps investors stay informed about significant events that could affect the company's value or stock price.
Senior Vice President, General Counsel and Secretary financial
"his resignation as the Company’s Senior Vice President, General Counsel and Secretary, effective as of April 10, 2026"
Securities Exchange Act of 1934 regulatory
"Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934"
emerging growth company regulatory
"405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Vanda Pharmaceuticals (VNDA) announce in this 8-K filing?
Vanda Pharmaceuticals announced the resignation of Timothy Williams as Senior Vice President, General Counsel and Secretary. He informed the company on March 29, 2026, and his departure will be effective April 10, 2026, as he intends to pursue other endeavors.
Who is resigning from Vanda Pharmaceuticals (VNDA) and what was his role?
Timothy Williams is resigning from Vanda Pharmaceuticals. He served as Senior Vice President, General Counsel and Secretary, overseeing the company’s top legal and corporate secretary functions as a key member of the senior executive team.
When will the resignation of Vanda Pharmaceuticals’ General Counsel take effect?
The resignation of Vanda Pharmaceuticals’ Senior Vice President, General Counsel and Secretary, Timothy Williams, will take effect on April 10, 2026. He notified the company of his decision on March 29, 2026, providing advance notice of his planned departure.
Why is Vanda Pharmaceuticals’ General Counsel Timothy Williams resigning?
Timothy Williams is resigning from his role as Senior Vice President, General Counsel and Secretary at Vanda Pharmaceuticals in order to pursue other endeavors. The filing states this reason without providing further detail about his future plans or destinations.
Does the Vanda Pharmaceuticals 8-K mention any replacement for the General Counsel?
The 8-K filing notes only that Timothy Williams has resigned as Senior Vice President, General Counsel and Secretary effective April 10, 2026. It does not identify or describe any successor or interim appointment in the disclosed text.
AI-generated analysis. How Rhea-AI works. Not financial advice.
